ImmunityBioInc.
N-803 (IL-15 Superagonist)(ImmunityBio, Inc.)은 High-risk Prostate Cancer 표적 세포·유전자 치료로, High-risk Prostate Cancer 영역에서 개발·상용화 중입니다. 작용기전: ADCC) and complement-dependent cytotoxicity (CDC). Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 80% (ClinicalTrials.gov NCT02384954). 차별점: novel immunotherapeutic targets.
High-risk Prostate Cancer
High-risk Prostate Cancer
Discontinued
ADCC) and complement-dependent cytotoxicity (CDC)
vedotin (BT8009) and dual-ADC combinations with
linker spaced IgG4 Fc fragment, soluble IL-15 Rα (sIL-15Rα), and IL-15(N72
retroviral therapy using expanded natural killer cells
humanized IgG1 mAb that binds to core 1 and/or extended core 1 O-glycans expressed by human cancer cells (inc
novel immunotherapeutic targets
ADCC) and complement-dependent cytotoxicity (CDC)
t cells through different mechanisms of action, including antibody-dependent cell-mediated cytotoxicity
apoptosis proteins and mimetic of the second mitochondrial-derived activator of caspases (IAPi/SMACm), induces systemic reversal
biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances i
resistance to proteolytic cleavage, and less frequent dosing schedule with minimum dosage for achieving the desired response compared
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
ImmunityBioInc.
N-803 (IL-15 Superagonist)(ImmunityBio, Inc.)은 High-risk Prostate Cancer 표적 세포·유전자 치료로, High-risk Prostate Cancer 영역에서 개발·상용화 중입니다. 작용기전: ADCC) and complement-dependent cytotoxicity (CDC). Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 80% (ClinicalTrials.gov NCT02384954). 차별점: novel immunotherapeutic targets.
High-risk Prostate Cancer
High-risk Prostate Cancer
Discontinued
ADCC) and complement-dependent cytotoxicity (CDC)
vedotin (BT8009) and dual-ADC combinations with
linker spaced IgG4 Fc fragment, soluble IL-15 Rα (sIL-15Rα), and IL-15(N72
retroviral therapy using expanded natural killer cells
humanized IgG1 mAb that binds to core 1 and/or extended core 1 O-glycans expressed by human cancer cells (inc
novel immunotherapeutic targets
ADCC) and complement-dependent cytotoxicity (CDC)
t cells through different mechanisms of action, including antibody-dependent cell-mediated cytotoxicity
apoptosis proteins and mimetic of the second mitochondrial-derived activator of caspases (IAPi/SMACm), induces systemic reversal
biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances i
resistance to proteolytic cleavage, and less frequent dosing schedule with minimum dosage for achieving the desired response compared
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.